Guest guest Posted September 21, 2005 Report Share Posted September 21, 2005 Dee, Your the one who gave me all the info in August.**smile** I called Pete a couple of months ago and asked him about the medication.I told him I got the info from a support group.He mentioned your name and I said yep thats where im from.He told me that 5-fluorocytosine and 4% flucytosin where the same med. and Ancobon is the generic of the two. You actualy sent me a post were Dr. Sobel said that if boric acid didnt work for glabrata that 4% flucytosine had a 99% cure rate.*remember* I kept all the info and now I can pass it along to others. ((HUGS)) Tami --- DeeTroll wrote: > HI all and thanks Tami SO much for bring that up > about another treatment for Glabrata, I hope > they're able to get something else that would work > as well and much less expensive. it'll be > interesting to see what they come up with. > > Anyway here a piece I have about the amphotericin B > and 5-fluorocytosine, I hope it helps. It's > something I sent elsewhere (I think) DUH.. Tami I > may have even sent this to you hon, I'm not sure. > (or maybe a shorter version) ? > > Dee~ > > ================== > Hi hon > > I'm trying to do more research for you on the > Torolupsis glabrata to see if there are any other > treatments recommended and ran across this one in > newborn babies.... but... what's the difference? It > may be a treatment you might be able to use as well. > Then I'll add some others, but I certainly don't > want to scare you and I know it's not your situation > but just for information. Also there's one here by > Sobel..... and he does of course mention the boric > acid....BUT..... in the very last line he suggests > something else as well. > > Also another one , different source and Sobels the > guy who's supposedly the best at yeast infections > hon, 98% of the references made were from him. > Fair warning it is long but I hope it helps. > > Hugs > Dee > ============================================ > 1. (this is the one with new babies) > > .....................Both patients had been treated > with surfactant, artificial ventilation, > intravascular catheters (arterial and venous), broad > spectrum antibiotics, and hyperalimentation, which > appear to be risk factors for T glabrata fungemia. > > (My note** hyperalimentation is intravenous > feeding with all the necessary vitamins, minerals > etc.. and I've no idea if it's because this was an > infant OR if it is a risk factor for anyone who has > T. Glabrata? No idea) > > A review of the literature indicates that T glabrata > is susceptible to amphotericin B and > 5-fluorocytosine and is resistant to fluconazole > (*Diflucan*) . In addition, it is less susceptible > to ketoconazole, clotrimazole, and itraconazole than > is Candida albicans. > > We recommend that T glabrata infections be treated > initially by reducing iatrogenic risk factors and > beginning amphotericin B therapy. If necessary, > 5-fluorocytosine should be added to the drug > regimen. > > SOURCE: > http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve & db=PubMed & list_uids=9\ 042184 & dopt=Citation > ====================================================== > > 2. This is the one about Dr. Sobel, and the very > last line he does offer a different treatment. > > > DURBAN, SOUTH AFRICA -- Physicians seeking reliably > effective therapy for Candida glabrata vaginitis > must dust off a treatment that was in its heyday in > the Crimean War era, Dr. Jack D. Sobel said at a > satellite conference held in conjunction with WONCA > 2001, the conference of the World Organization of > Family Doctors. > > Treatment with intravaginal boric acid gelatin > capsules may have a 19th-century ring to it, but it > also has a 70% cure rate in C. glabrata > vaginitis--and that's a lot better than can be > achieved with modern azole therapy. > > " Candida glabrata is the Achilles' heel of azole > therapy. None of the azoles do well with Candida > glabrata, " observed Dr. Sobel, professor of medicine > at Wayne State University, Detroit. > > The success rate with azole therapy in C. glabrata > vaginitis is so spotty--producing cures in 50% of > treated patients or less--that these agents are best > skipped in women for whom an azole has previously > failed. > > Instead, turn to 600-mg boric acid capsules inserted > into the vagina once or twice daily for 14 days, he > advised at the satellite conference sponsored by > Pfizer Inc. > > If boric acid fails, the drug of choice is topical > 4% flucytosine once daily for 14 days. The cure rate > with this treatment is greater than 90%. > > source: > http://www.findarticles.com/p/articles/mi_m0CYD/is_15_36/ai_77611262 > > > =============================================== > 3. > > Hon I 'Don't' think this relates to you as these > were patients with 'other' serious diseases and the > T Glabrata it's more known in those who do have > compromised immune systems such as with diabetes, > but for what it's worth. > > Torulopsis glabrata fungemia--a clinical > pathological study. > > Berkowitz ID, Robboy SJ, Karchmer AW, Kunz LJ. > > The clinical findings, pathologic features, and > outcome were investigated in 46 patients in whom > Torulopsis glabrata was isolated in 131 specimens of > blood. > > Nineteen of the patients had only a single positive > blood culture and no evidence of systemic yeast > infection, while 27 patients had a clinically > significant fungemia based upon the occurrence of 2 > or more positive blood cultures, or the combination > of a positive blood culture and isolation of the > organism from a closed body cavity or demonstration > of the yeast in tissue sections. > > The predisposing factors for the development of > fungemia included the presence of intravenous lines, > indwelling Foley catheters, antibiotics and surgery, > especially when the gastrointestinal tract was > involved. > > Only 22% of patients received either steroids or > cytostatic agents. Possible portals of entry were > suggested by the prior isolation of the organism > from urine, sputum, wounds, and central venous > catheter tips in most of the patients. Twelve of 27 > patients with clinically significant fungemia were > treated. > > The initial mode of therapy in nine patients was > removal of intravenous lines because of the clinical > suspicion of catheter related sepsis. Seven of the > patients improved rapidly and one more after > amphotericin B was subsequently administered. > Amphotericin B was the initial therapy in three > cases. > > One patient was cured while another died of an > unrelated infection. Five patients were not treated > although the isolation of T. glabrata had been > reported; the fact that the presence of the organism > was felt to be unimportant was considered to be a > factor in the delay of treatment. In the remaining > 10 patients the organism was isolated only after the > patient had died. > > Division of the patients into four groups based upon > whether the individuals survived, died of unrelated > disease, died with potentially lethal infection, or > died with T. glabrata infection significantly > contributing to death, revealed a spectrum of > disease, certain signs of which appeared to be of > predictive value as prognostic indices of survival > and severity of the infection. > > Seven patients with transient fungemia experienced > an acute episode of high spiking fever (greater than > 102.5 degrees F), rigors and/or hypotension, six of > whom improved after the intravenous catheter was > removed, suggesting a catheter-related sepsis. In > contrast, persistent low grade fever (less than > 102.5 degrees F) characterized eight of the nine > patients in whom T. glabrata infection was > considered either potentially lethal, or > contributing significantly to death. > > A deteriorating clinical course with organ failure > was also associated with this latter category of > patients. Catheter-induced specticemia was > considered in only two patients in this category. > The autopsy and clinical findings in this > investigation as well as reported experimental > studies suggest that T. glabrata is an organism of > low virulence. The patients' underlying disease > (e.g., neoplasia) and coexisting bacterial infection > are the most important factors responsible for > death. > > === message truncated === __________________________________ Yahoo! Mail - PC Magazine Editors' Choice 2005 http://mail.yahoo.com Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 21, 2005 Report Share Posted September 21, 2005 HI Tami.. I'm just so glad you mentioned that other drug for Glabrata.....I didn't even give it a thought at the time (old timers setting in here, haha) there is just so much to say at times I sure forget or I think of it after I send something, so that was GREAT that 'you' remembered, *SMILE* Glad you talked to Pete too, I just hope they can find something you can use that isn't so sensitive for you OR expensive. *sigh* Hugs Dee~ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.